This page will host Events plug-in for all Clarion and trade events.

Recent Quotes
My Watchlist
Indicators
EL&P Market Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Aquestive Therapeutics, Inc. - Common Stock (NQ:AQST)

3.470 +0.230 (+7.10%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 27, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Aquestive Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Aquestive Therapeutics, Inc. - AQST
From Pomerantz LLP
Via GlobeNewswire
News headline image
AQST INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Aquestive Therapeutics
From Faruqi & Faruqi LLP
Via GlobeNewswire
News headline image
AQUESTIVE ALERT: Bragar Eagel & Squire, P.C. is Investigating Aquestive Therapeutics, Inc. on Behalf of Aquestive Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Aquestive Therapeutics, Inc. - AQST
From Pomerantz LLP
Via GlobeNewswire
News headline image
Kaplan Fox & Kilsheimer LLP is Investigating Aquestive Therapeutics, Inc. (AQST) for Potential Securities Law Violations
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
News headline image
Kaplan Fox &amp; Kilsheimer LLP is Investigating Aquestive Therapeutics, Inc. (AQST) for Potential Securities Law Violations
Via TheNewswire.com
News headline image
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Aquestive Therapeutics
From Faruqi & Faruqi LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aquestive Therapeutics, Inc. - AQST
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Aquestive Therapeutics
From Faruqi & Faruqi, LLP
Via Business Wire
News headline image
Aquestive Therapeutics Announces Regulatory Development for Anaphylm™ (dibutepinephrine) Sublingual Film and Provides Business Update
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
News headline image
Aquestive Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
News headline image
Aquestive Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
News headline image
Aquestive Therapeutics Announces Leadership Expansion to Support Growth
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
News headline image
Aquestive Therapeutics to Participate in a Fireside Chat Hosted by Piper Sandler
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
News headline image
Aquestive Therapeutics to Attend 2025 ACAAI Annual Meeting
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
News headline image
Aquestive Therapeutics to Report Third Quarter 2025 Financial Results and Recent Business Highlights on November 5 and Host Conference Call on November 6 at 8:00 a.m. ET
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
News headline image
Aquestive Therapeutics Broadens Patent Estate for Anaphylm™
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
News headline image
Aquestive Therapeutics Announces that FDA Will Not Require an Advisory Committee Meeting to Discuss New Drug Application for Anaphylm™
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
News headline image
Aquestive Therapeutics to Participate in Upcoming September Investor Conferences
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
News headline image
Aquestive Therapeutics Announces Pricing of $85 Million Underwritten Offering of Common Stock
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
News headline image
Aquestive Therapeutics Announces $75M Strategic Funding Agreement with RTW to Support the Potential Launch of Anaphylm™ (epinephrine) Sublingual Film
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
News headline image
Aquestive Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
News headline image
Aquestive Therapeutics to Report Second Quarter 2025 Financial Results and Recent Business Highlights on August 11 and Host Conference Call on August 12 at 8:00 a.m. ET
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
News headline image
Aquestive Therapeutics Names Sherry Korczynski as Chief Commercial Officer
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
News headline image
Aquestive Therapeutics Provides International Expansion Update for Anaphylm™ (epinephrine) Sublingual Film
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
News headline image
Aquestive Therapeutics to Participate in Leerink Partners Therapeutics Forum: I&I and Metabolism
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
News headline image
Aquestive Therapeutics to Present Positive Data from Pharmacokinetic and Pharmacodynamic Studies of Anaphylm™ (epinephrine) Sublingual Film at the CFAAR Food Allergy Summit
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
News headline image
Aquestive Therapeutics Announces FDA Acceptance of New Drug Application and PDUFA Date for Anaphylm™ for the Treatment of Severe Allergic Reactions
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
News headline image
Aquestive Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
News headline image
Aquestive Therapeutics to Participate in Citizens Life Sciences Conference
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.